Prevail Therapeutics Inc. Gains 82%
Tue, Dec 15, 2020 at 05:30 PM
Prevail Therapeutics Inc. (PRVL:NASDAQ) shot up at $22.75, representing a gain of 82%. On Mon 14 Dec 20, PRVL:NASDAQ touched a New 2-Week High of $12.5. The stock got featured on our News Catalysts scanner on Tue 15 Dec 20 at 03:51 PM in the 'MERGER' category. From Mon 30 Nov 20, the stock recorded 50.00% Up Days and 54.55% Green Days
The share price of the company has been moving sideways in recent weeks.
About Prevail Therapeutics Inc. (PRVL:NASDAQ)
Prevail Therapeutics Inc is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. Its pipeline products include PR001, PR006 and PR 004.
Top 10 Gainers:
- Concord Medical Services Holdings Limited (CCM:NYSE), 179.46%
- Anchiano Therapeutics Ltd (ANCN:NASDAQ), 87.01%
- Prevail Therapeutics Inc. (PRVL:NASDAQ), 82%
- MicroVision, Inc. (MVIS:NASDAQ), 34.5%
- ELYS (ELYS:NASDAQ), 29.03%
- Marathon Patent Group, Inc. (MARA:NASDAQ), 27.62%
- Arvinas, Inc. (ARVN:NASDAQ), 27.18%
- Barnwell Industries, Inc. (BRN:NYSEMKT), 26.66%
- Sensus Healthcare, Inc. (SRTS:NASDAQ), 26.4%
- Solid Biosciences Inc. (SLDB:NASDAQ), 23.38%